Last reviewed · How we verify
MEDI3617
At a glance
| Generic name | MEDI3617 |
|---|---|
| Also known as | MEDI-3617 |
| Sponsor | F. Stephen Hodi, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (PHASE1)
- A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI3617 CI brief — competitive landscape report
- MEDI3617 updates RSS · CI watch RSS
- F. Stephen Hodi, MD portfolio CI